Could immune cells tame advanced bladder cancer? early trial aims to find out
NCT ID NCT07204496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study will test a new type of immune cell therapy in 20 people with advanced bladder cancer that hasn't responded to standard treatments. The therapy uses the patient's own γδ-T cells, which are grown in a lab and then infused back to attack the cancer. The main goal is to see if the treatment is safe and can slow down the cancer's growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- γδ-T cell infusion (a type of immune cell therapy using the patient's own cells)
- What this could lead to
- If this works, it could offer a new way to control advanced bladder cancer, potentially turning it into a manageable chronic condition and improving quality of life.
- What could go wrong
- This is a very early, small trial (20 patients) testing safety and basic effectiveness. The therapy may not shrink tumors or extend survival, and there could be side effects from the cell infusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.